WHO ICTRP trial
A SINGLE-DOSE PHARMACOKINETIC AND BIOAVAILABILITY STUDY OF A GENERIC…
PER-092-12 · Registro Peruano de Ensayos Clínicos (REPEC)
Key facts
| Trial ID | PER-092-12 |
|---|---|
| Public title | A SINGLE-DOSE PHARMACOKINETIC AND BIOAVAILABILITY STUDY OF A GENERIC LIPOSOME-ENCAPSULATED DOXORUBICIN HYDROCHLORIDE FORMULATION IN SUBJECTS WITH EPITHELIAL OVARIAN CARCINOMA WHO HAVE FAILED PLATINUM-BASED CHEMOTHERAPY |
| Scientific title | A SINGLE-DOSE PHARMACOKINETIC AND BIOAVAILABILITY STUDY OF A GENERIC LIPOSOME-ENCAPSULATED DOXORUBICIN HYDROCHLORIDE FORMULATION IN SUBJECTS WITH EPITHELIAL OVARIAN CARCINOMA WHO HAVE FAILED PLATINUM-BASED CHEMOTHERAPY |
| Primary sponsor | TOLMAR Inc, |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Study type | Interventional |
| Phase | IV |
| Interventions | THIS STUDY IS DESIGNED TO EVALUATE THE BA, PK, AND SAFETY OF TOLMAR FORMULATION AT THE DOXIL STANDARD DOSE OF 50 MG/M2. AN ESTIMATE OF THE RELATIVE BA (IE, AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE [AUC] OF INVESTIGATIONAL PRODUCT… |
| Registration date | Feb 21, 2013 |
| Target size | 26 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: